MedTrace Logo

Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease

NCT02389413 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2017-06-01

No results posted yet for this study

Summary

The aim of this study is to evaluate the safety, tolerability and preliminary efficacy of PQ912 in subjects with Mild Cognitive Impairment (MCI) due to Alzheimers Disease (AD) or mild dementia due to AD.

Conditions

Interventions

DRUG

PQ912 oral

OTHER

Placebo

Sponsors & Collaborators

  • Julius Clinical

    collaborator INDUSTRY

  • Amsterdam UMC, location VUmc

    collaborator OTHER

  • Vivoryon Therapeutics N.V.

    lead INDUSTRY

Principal Investigators

  • Frank Weber, Dr. · Vivoryon Therapeutics N.V.

  • Philip Scheltens, Prof. Dr. · VUmc Alzheimer Centre (p: +31 20 4440816)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2017-04-30
Completion
2017-04-30

Countries

  • Belgium
  • Finland
  • France
  • Germany
  • Netherlands
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02389413 on ClinicalTrials.gov